North America Pharmacogenomics Market (2019-2025)
The North America Pharmacogenomics Market would witness market growth of 8.1% CAGR during the forecast period (2019–2025).
Pharmacogenomics is helpful in treating cancer and has improved the patient survival rate, along with reducing the unnecessary cost due to unresponsive treatment by patients. Therefore, pharmacogenomics for cancer therapy has created multiple crucial discoveries in the existing cancer treatment; thereby, driving the market growth over the forecast period. The growing expenditure in R&D and increasing rate of adverse reactions have augmented the adoption of pharmacogenomics across the globe. Also, there is a significant increase in the number of research studies which are related to next-generation sequencing. This is expected to increase the demand for pharmacogenomic tests in the future.
Technological advancements along with molecular diagnostics procedure to better understand the genetic structure of the individual patients is expected to further boost the growth of pharmacogenomics market over the forecast period.
Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
Scope of the Study
Market Segmentation:
By Application
Pharmacogenomics is helpful in treating cancer and has improved the patient survival rate, along with reducing the unnecessary cost due to unresponsive treatment by patients. Therefore, pharmacogenomics for cancer therapy has created multiple crucial discoveries in the existing cancer treatment; thereby, driving the market growth over the forecast period. The growing expenditure in R&D and increasing rate of adverse reactions have augmented the adoption of pharmacogenomics across the globe. Also, there is a significant increase in the number of research studies which are related to next-generation sequencing. This is expected to increase the demand for pharmacogenomic tests in the future.
Technological advancements along with molecular diagnostics procedure to better understand the genetic structure of the individual patients is expected to further boost the growth of pharmacogenomics market over the forecast period.
Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
Scope of the Study
Market Segmentation:
By Application
- Sequencing
- Polymerase Chain Reaction
- Electrophoresis
- Mass Spectrometry
- Microarray
- Others
- Oncology
- Psychiatry
- Infectious Diseases
- Neurological Diseases
- Pain management
- Cardiovascular Diseases
- Others
- Hospitals and Clinics
- Research Institutions
- Academic Institutes
- US
- Canada
- Mexico
- Rest of North America
- Abbott Laboratories
- Empire Genomics LLC
- Illumina, Inc.
- Oneome LLC
- Myriad Genetics Inc.
- Thermo Fisher Scientific, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bayer AG
- Opko Health, Inc.
- Becton, Dickinson and Company
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Pharmacogenomics Market, by Application
1.4.2 North America Pharmacogenomics Market, by Application
1.4.3 North America Pharmacogenomics Market, by End User
1.4.4 North America Pharmacogenomics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY
3.1.1 North America Sequencing Market by Country
3.1.2 North America Polymerase Chain Reaction Market by Country
3.1.3 North America Electrophoresis Market by Country
3.1.4 North America Mass Spectrometry Market by Country
3.1.5 North America Microarray Market by Country
3.1.6 North America Others Market by Country
CHAPTER 4. NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION
4.1.1 North America Oncology Market by Country
4.1.2 North America Psychiatry Market by Country
4.1.3 North America Infectious Diseases Market by Country
4.1.4 North America Neurological Diseases Market by Country
4.1.5 North America Pain Management Market by Country
4.1.6 North America Cardiovascular Diseases Market by Country
4.1.7 North America Others Market by Country
CHAPTER 5. NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER
5.1.1 North America Hospitals and Clinics Market by Country
5.1.2 North America Research Institutions Market by Country
5.1.3 North America Academic Institutes Market by Country
CHAPTER 6. NORTH AMERICA PHARMACOGENOMICS MARKET BY COUNTRY
6.1 USA Pharmacogenomics Market
6.1.1 USA Pharmacogenomics Market by Technology
6.1.2 USA Pharmacogenomics Market by Application
6.1.3 USA Pharmacogenomics Market by End User
6.2 Canada Pharmacogenomics Market
6.2.1 Canada Pharmacogenomics Market by Technology
6.2.2 Canada Pharmacogenomics Market by Application
6.2.3 Canada Pharmacogenomics Market by End User
6.3 Mexico Pharmacogenomics Market
6.3.1 Mexico Pharmacogenomics Market by Technology
6.3.2 Mexico Pharmacogenomics Market by Application
6.3.3 Mexico Pharmacogenomics Market by End User
6.4 Rest of North America Pharmacogenomics Market
6.4.1 Rest of North America Pharmacogenomics Market by Technology
6.4.2 Rest of North America Pharmacogenomics Market by Application
6.4.3 Rest of North America Pharmacogenomics Market by End User
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Pharmacogenomics Market, by Application
1.4.2 North America Pharmacogenomics Market, by Application
1.4.3 North America Pharmacogenomics Market, by End User
1.4.4 North America Pharmacogenomics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY
3.1.1 North America Sequencing Market by Country
3.1.2 North America Polymerase Chain Reaction Market by Country
3.1.3 North America Electrophoresis Market by Country
3.1.4 North America Mass Spectrometry Market by Country
3.1.5 North America Microarray Market by Country
3.1.6 North America Others Market by Country
CHAPTER 4. NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION
4.1.1 North America Oncology Market by Country
4.1.2 North America Psychiatry Market by Country
4.1.3 North America Infectious Diseases Market by Country
4.1.4 North America Neurological Diseases Market by Country
4.1.5 North America Pain Management Market by Country
4.1.6 North America Cardiovascular Diseases Market by Country
4.1.7 North America Others Market by Country
CHAPTER 5. NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER
5.1.1 North America Hospitals and Clinics Market by Country
5.1.2 North America Research Institutions Market by Country
5.1.3 North America Academic Institutes Market by Country
CHAPTER 6. NORTH AMERICA PHARMACOGENOMICS MARKET BY COUNTRY
6.1 USA Pharmacogenomics Market
6.1.1 USA Pharmacogenomics Market by Technology
6.1.2 USA Pharmacogenomics Market by Application
6.1.3 USA Pharmacogenomics Market by End User
6.2 Canada Pharmacogenomics Market
6.2.1 Canada Pharmacogenomics Market by Technology
6.2.2 Canada Pharmacogenomics Market by Application
6.2.3 Canada Pharmacogenomics Market by End User
6.3 Mexico Pharmacogenomics Market
6.3.1 Mexico Pharmacogenomics Market by Technology
6.3.2 Mexico Pharmacogenomics Market by Application
6.3.3 Mexico Pharmacogenomics Market by End User
6.4 Rest of North America Pharmacogenomics Market
6.4.1 Rest of North America Pharmacogenomics Market by Technology
6.4.2 Rest of North America Pharmacogenomics Market by Application
6.4.3 Rest of North America Pharmacogenomics Market by End User
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis
LIST OF TABLES
TABLE 1 NORTH AMERICA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA SEQUENCING MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA SEQUENCING MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA ELECTROPHORESIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA ELECTROPHORESIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA MASS SPECTROMETRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA MASS SPECTROMETRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA MICROARRAY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA MICROARRAY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA ONCOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA ONCOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA PSYCHIATRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA PSYCHIATRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA INFECTIOUS DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA INFECTIOUS DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA PAIN MANAGEMENT MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA PAIN MANAGEMENT MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 NORTH AMERICA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 NORTH AMERICA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 NORTH AMERICA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 NORTH AMERICA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 NORTH AMERICA PHARMACOGENOMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 42 NORTH AMERICA PHARMACOGENOMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 43 USA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 44 USA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 45 USA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 46 USA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 47 USA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 48 USA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 49 USA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 50 USA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 51 CANADA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 52 CANADA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 53 CANADA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 54 CANADA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 55 CANADA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 CANADA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 CANADA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 58 CANADA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 59 MEXICO PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 60 MEXICO PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 61 MEXICO PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 62 MEXICO PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 63 MEXICO PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 64 MEXICO PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 65 MEXICO PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 66 MEXICO PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 67 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 68 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 69 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 70 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 71 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 72 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 73 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 74 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 75 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 76 KEY INFORMATION - EMPIRE GENOMICS LLC
TABLE 77 KEY INFORMATION – ILLUMINA, INC.
TABLE 78 KEY INFORMATION – ONEOME LLC
TABLE 79 KEY INFORMATION – MYRIAD GENETICS INC.
TABLE 80 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 81 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 82 KEY INFORMATION – BAYER AG
TABLE 83 KEY INFORMATION – OPKO HEALTH, INC.
TABLE 84 KEY INFORMATION – BECTON, DICKINSON AND COMPANY
TABLE 1 NORTH AMERICA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA SEQUENCING MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA SEQUENCING MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA ELECTROPHORESIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA ELECTROPHORESIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA MASS SPECTROMETRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA MASS SPECTROMETRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA MICROARRAY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA MICROARRAY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA ONCOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA ONCOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA PSYCHIATRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA PSYCHIATRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA INFECTIOUS DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA INFECTIOUS DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA PAIN MANAGEMENT MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA PAIN MANAGEMENT MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 NORTH AMERICA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 NORTH AMERICA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 NORTH AMERICA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 NORTH AMERICA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 NORTH AMERICA PHARMACOGENOMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 42 NORTH AMERICA PHARMACOGENOMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 43 USA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 44 USA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 45 USA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 46 USA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 47 USA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 48 USA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 49 USA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 50 USA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 51 CANADA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 52 CANADA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 53 CANADA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 54 CANADA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 55 CANADA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 CANADA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 CANADA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 58 CANADA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 59 MEXICO PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 60 MEXICO PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 61 MEXICO PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 62 MEXICO PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 63 MEXICO PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 64 MEXICO PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 65 MEXICO PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 66 MEXICO PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 67 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION
TABLE 68 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION
TABLE 69 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 70 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 71 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 72 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 73 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION
TABLE 74 REST OF NORTH AMERICA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION
TABLE 75 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 76 KEY INFORMATION - EMPIRE GENOMICS LLC
TABLE 77 KEY INFORMATION – ILLUMINA, INC.
TABLE 78 KEY INFORMATION – ONEOME LLC
TABLE 79 KEY INFORMATION – MYRIAD GENETICS INC.
TABLE 80 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 81 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 82 KEY INFORMATION – BAYER AG
TABLE 83 KEY INFORMATION – OPKO HEALTH, INC.
TABLE 84 KEY INFORMATION – BECTON, DICKINSON AND COMPANY
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 SWOT ANALYSIS: ABBOTT LABORATORIES
FIG 3 SWOT ANALYSIS: THERMO FISHER SCIENTIFIC, INC.
FIG 4 SWOT ANALYSIS: BAYER AG
FIG 5 SWOT ANALYSIS: BECTON, DICKINSON AND COMPANY
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 SWOT ANALYSIS: ABBOTT LABORATORIES
FIG 3 SWOT ANALYSIS: THERMO FISHER SCIENTIFIC, INC.
FIG 4 SWOT ANALYSIS: BAYER AG
FIG 5 SWOT ANALYSIS: BECTON, DICKINSON AND COMPANY
